AI-generated summary
The authors report a prospective study of 44 patients with moderate to severe meibomian gland dysfunction treated with four sessions of a new intense pulsed light device over about seven weeks. They found improvements in dryness, symptoms and several clinical signs, with no complications reported, and describe the treatment as safe and effective. The study had no control group, so these findings are uncontrolled.
- Participants
- 44
- Who or what was studied
- Patients with moderate to severe meibomian gland dysfunction causing dry eye disease, 44 consecutive patients (88 eyes), aged 22 to 78 years, all Fitzpatrick skin types I to VI.
- Limits stated in the abstract
- The abstract describes a single prospective study without a control group, so improvements cannot be attributed to the device with certainty.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Energy density (fluence)
- 8J/cm2
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Dry eye, Fitzpatrick scale. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.